NULISA data featured in 46 presentations at #CTAD2026: 10 oral presentations and 36 posters from more than 30 academic, clinical, and biopharma groups across 10 countries.
The research covers brain-derived and CNS-selective p-tau217, biomarker readouts from interventional trials including Auτonomy, FINGER, and APOLLOE4, plasma proteomic responses to lecanemab and ARIA, synaptic and inflammatory signatures, and conditions beyond Alzheimer’s disease such as CTE, TDP-43 pathology, and primary tauopathies.
Download the full listing here: na2.hubs.ly/H08_XfP0
Talks run Nov 16 to 19 in the Ballroom (4th floor). Posters are across Sessions 1 to 3 in the Atrium and Gloucester rooms (3rd floor). Please stop by and talk with the presenters about their work!
Alamar colleagues will be onsite and welcome discussion about your Alzheimer's research needs.
The research covers brain-derived and CNS-selective p-tau217, biomarker readouts from interventional trials including Auτonomy, FINGER, and APOLLOE4, plasma proteomic responses to lecanemab and ARIA, synaptic and inflammatory signatures, and conditions beyond Alzheimer’s disease such as CTE, TDP-43 pathology, and primary tauopathies.
Download the full listing here: na2.hubs.ly/H08_XfP0
Talks run Nov 16 to 19 in the Ballroom (4th floor). Posters are across Sessions 1 to 3 in the Atrium and Gloucester rooms (3rd floor). Please stop by and talk with the presenters about their work!
Alamar colleagues will be onsite and welcome discussion about your Alzheimer's research needs.